- Adagene Inc ADAG has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc MRK.
- The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Merck's Keytruda (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies.
- ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb developed to treat advanced solid tumors and non-Hodgkin's lymphoma.
- Related: Adagene To Test Its Anti-CTLA-4 Antibodies In Combination With Keytruda In Solid Tumors.
- Price Action: ADAG shares closed 4.02% lower at $17.80 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
